12 Most Promising Biotech Stocks According to Wall Street Analysts

4. CRISPR Therapeutics AG (NASDAQ:CRSP)

Analyst Upside: 73.65% 

CRISPR Therapeutics AG (NASDAQ:CRSP) uses its patented CRISPR/Cas9 platform to create revolutionary gene-based medications for severe illnesses. Gene editing technique is used by the CRISPR/Cas9 platform to enable precise modifications to genomic DNA. The company’s product portfolio includes therapeutic projects in oncology, rare diseases, regenerative medicine, and other medical fields.

The main goal of CRISPR Therapeutics AG (NASDAQ:CRSP) is the strategic advancement of its clinical trial portfolio in the areas of autoimmune, diabetes, cancer, and cardiovascular diseases. For the company, the FDA’s approval and introduction of CASGEVY, a gene therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) in patients aged 12 and up, has generated significant momentum. Additionally, the business has acquired regulatory permission for the medicine in several countries worldwide, including the European Union, Canada, Switzerland, and Great Britain, among others, and product launches are currently in progress. The drug’s continuous rollout is accelerating, and in 2025, fresh cell patient collection initiations are predicted to rise sharply. Globally, more than 50 CASGEVY-approved treatment centers (ATCs) have been operational.

CRISPR Therapeutics AG (NASDAQ:CRSP)’s balance sheet is robust as of December 31, 2024, with approximately $1.9 billion in marketable securities, cash, and cash equivalents. Analysts have a Moderate Buy rating on the stock. Over the past three months, 20 Wall Street analysts have set a 12-month price target with an average of $71.58. The high forecast is $120.00, while the low is $32.00. This average target reflects a potential upside of 73.65% from the current price of $41.22.